DUBLIN--(BUSINESS WIRE)--The "Oral Mucositis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments" report has been added to Research and Markets' offering.
Oral mucositis is the most common complication of chemotherapy, and occurs usually in the people suffering from head and neck cancer. It causes damage to mucosal lining of the mouth which results in formation of ulcers and infections.
The disease occurs usually occurs after 5 to 10 days of a chemotherapy process in cancer patients. Oral mucositis leads to different problems such as severe pain in mouth, lack of nutrition due to inability to eat, increased risk of infections due to open sores in the oral cavity. The disease usually lasts for one week to six weeks or more.
Some of the symptoms associated with oral mucositis are open sores or bleeding, pain, redness or swelling, white patches, dry mouth, diarrhea, nausea, blood in mouth, thicker saliva in the mouth and difficulty in talking or swallowing.
Oral mucositis can be treated by using antiseptic mouth rinses, pain killer medicines, water-soluble lubricating agents, bland rinses and mucosal coating agents.
Oral Mucositis Therapeutics Pipeline Analysis
Drug manufacturing companies are constantly in the quest to find better and new treatment strategies with potential targets such as glucocorticoid receptor and superoxide dismutase which can also prove to be effective in oral mucositis treatment.
The U.S. Food and Drug Administration (USFDA) has granted various designations including orphan drug and fast track status to many drugs which are driving the growth of the pipeline.
Key Topics Covered:
1. Research Background
2. Research Methodology
3. Executive Summary
4. Pipeline Outlook
5. Oral Mucositis Pipeline Analysis By Phase (2017)
6 Competitive Landscape
7 Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/6wcdgm/oral_mucositis